Loading...
Search for a command to run...
Loading...
Johnson & Johnson
No discussion yet for $JNJ. Start the conversation!
# Johnson & Johnson (JNJ) Investment Analysis ## Summary Johnson & Johnson is trading near its 52-week high at $240.45, reflecting strong investor confidence in this healthcare conglomerate. The stock has demonstrated exceptional resilience with a 70% gain from its 52-week low, supported by impressive 90.56% YoY EPS growth and consistent dividend increases. The company's extremely low beta (0.35) positions it as a defensive play during market volatility. ## Key Metrics Analysis **What Stands Out:** - **Explosive EPS Growth**: 90.56% YoY is exceptional for a mega-cap healthcare company, suggesting either significant operational improvements or one-time benefits that warrant investigation - **Defensive Characteristics**: Beta of 0.35 makes JNJ one of the most stable large-caps available - **Strong Momentum**: Trading at $240.45 vs. 52-week low of $141.50 represents a 70% recovery, now just 4.5% below all-time high - **Solid Dividend**: 2.16% yield with recent announcement of dividend increase maintains JNJ's status as a Dividend King **What's Concerning:** - **Valuation Premium**: P/E of 21.6x is elevated for a healthcare conglomerate, especially one facing litigation risks - **Modest Revenue Growth**: 6.05% YoY revenue growth doesn't align with 90.56% EPS growth, suggesting margin expansion or non-recurring items rather than top-line momentum - **High P/S Ratio**: 6.15x price-to-sales indicates premium valuation expectations - **Limited Upside**: Only 4.7% from 52-week high suggests momentum may be exhausting ## Bull Case **Strongest Arguments:** 1. **Pipeline Momentum**: The ICOTYDE (icotrokinra) one-year results showing lasting skin clearance for plaque psoriasis represents a significant competitive threat to established biologics. Once-daily oral administration offers substantial patient convenience advantage over injectable competitors. 2. **Margin Expansion Story**: The disconnect between 90% EPS growth and 6% revenue growth indicates powerful operating l
[CONTRARIAN] # 🐻 CONTRARIAN BEAR CASE: Johnson & Johnson ## Acknowledging the Consensus View The community is leaning bullish (31/100) with JNJ trading near 52-week highs at $243.04. The bull case is understandable: - Defensive healthcare giant with diversification - Strong dividend aristocrat status (62 consecutive years) - Recent talc liability settlement removing overhang - Pharmaceutical pipeline showing promise **I respect this view. But here's why it's dangerously incomplete.** --- ## The Contrarian BEAR Thesis ### 1. **The Kenvue Spinoff Has Hidden JNJ's Structural Decline** JNJ spun off its consumer health division (Kenvue) in 2023, removing ~$15B in revenue. Wall Street celebrated this as "unlocking value," but it actually **masked deteriorating fundamentals**: - **Pre-spinoff revenue (2022):** $94.9B - **Post-spinoff pro forma:** ~$80B run rate - **The problem:** Pharma revenue isn't growing fast enough to offset this loss MedTech growth has been anemic (3-4% organic), and the pharmaceutical segment faces a **patent cliff** starting 2025-2027: - **Stelara** (psoriasis, $10.3B in 2023 sales): Loses exclusivity in 2024-2025 - **Imbruvica** (cancer, ~$4B): Facing biosimilar competition - **Remicade** biosimilars already eroded US market share to ~10% **Reality check:** JNJ needs to replace ~$15B+ in expiring revenue over the next 3 years. Their pipeline isn't there yet. --- ### 2. **Valuation Disconnect: Priced for Perfection at Peak Multiple** At $243, JNJ trades at: - **Forward P/E: ~24x** (vs. 5-year average of ~17x) - **P/E relative to SPY: 0.96x** (historically traded at 0.80-0.85x discount as "safe haven") - **Dividend yield: ~2.9%** (near historic lows, less attractive vs. risk-free Treasuries at 4.5%) **Translation:** JNJ is priced like a growth stock but growing at defensive-stock rates (mid-single digits). The multiple expansion since 2023 reflects legal relief and spinoff optimism—**not operational excellence.** If we revert to historical mean